mRNA Delivery System for Targeting Antigen-Presenting Cells In Vivo

Cristina Fornaguera, Marta Guerra-Rebollo, Miguel Ángel Lázaro, Cristina Castells-Sala, Oscar Meca-Cortés, Victor Ramos-Pérez, Anna Cascante, Núria Rubio, Jerónimo Blanco, Salvador Borrós

Producció científica: Article en revista indexadaArticleAvaluat per experts

72 Cites (Scopus)


The encapsulation of mRNA in nanosystems as gene vaccines for immunotherapy purposes has experienced an exponential increase in recent years. Despite the many advantages envisaged within these approaches, their application in clinical treatments is still limited due to safety issues. These issues can be attributed, in part, to liver accumulation of most of the designed nanosystems and to the inability to transfect immune cells after an intravenous administration. In this context, this study takes advantage of the known versatile properties of the oligopeptide end-modified poly (β-amino esters) (OM-PBAEs) to complex mRNA and form discrete nanoparticles. Importantly, it is demonstrated that the selection of the appropriate end-oligopeptide modifications enables the specific targeting and major transfection of antigen-presenting cells (APC) in vivo, after intravenous administration, thus enabling their use for immunotherapy strategies. Therefore, with this study, it can be confirmed that OM-PBAE are appropriate systems for the design of mRNA-based immunotherapy approaches aimed to in vivo transfect APCs and trigger immune responses to fight either tumors or infectious diseases.

Idioma originalAnglès
Número d’article1800335
RevistaAdvanced Healthcare Materials
Estat de la publicacióPublicada - 5 de set. 2018


Navegar pels temes de recerca de 'mRNA Delivery System for Targeting Antigen-Presenting Cells In Vivo'. Junts formen un fingerprint únic.

Com citar-ho